What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call

Ultragenyx (RARE) reported Q3 2026 earnings, highlighting FDA approvals for GENGLYCOS and FAYUVI, two new gene therapies. The company also announced setbacks in clinical trials for GTX-102 and UX701, leading to program terminations and workforce reductions. Revenue guidance for 2026 was reaffirmed at $730M-$760M, with profitability expected in 2027. The company aims to reduce expenses by 50% by 2027.

Ultragenyx (RARE) is ending two studies and refocusing R&D. The company reaffirmed its 2027 GAAP profitability target, approved two drugs, and announced a 20% workforce reduction. Its average 12-month price target is $26.40, implying 59% upside.

Ultragenyx Pharmaceutical Inc. (RARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Media Jess Rowlands media@ultragenyx.com Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027 Third quart

Ultragenyx reported Q3 2026 revenue of $173M, reaffirming 2026 guidance of $730M-$760M. The company announced expense reductions, including a 20% headcount cut, and expects 2027 profitability. FDA approved two gene therapies, GENGLYCOS and FAYUVI, with PRVs sold for $413M combined.

Ultragenyx Pharmaceutical Inc. reports Q3 earnings, with analysts expecting a loss of $1.10 per share on revenue of $182.19M, down 15% sequentially. The company recently gained FDA approvals for two gene therapies, FAYUVI and GENGLYCOS, and sold Priority Review Vouchers for $413M. Investors will watch for commercial traction and revenue guidance. The stock has a mean price target of $26.25, implying 61% upside from its current price of $16.30.

Ultragenyx Pharmaceutical (RARE) received conditional approval from the U.K. drug regulator for its rare disease therapy, Dojolvi, to treat long-chain fatty acid oxidation disorders (LC-FAOD).